![Jonathan Aballi, President and Chief Executive Officer. [NASDAQ XGN] at Exagen](https://exagen.wpenginepowered.com/wp-content/uploads/2022/11/John-A-Headshot.png)
Exagen
Healthcare Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1261 Liberty Way, Vista, California, 920...Phone Number
(888) 452-1522Website
www.exagen.comRevenue
$68.4 MillionStock Symbol
XGNIndustry
ZI Rank: 8
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
4
3
5
11
8
About Exagen
Exagen is a United Statesbased life sciences company that develops and commercializes advanced diagnostic testing solutions focused on autoimmune diseases, helping healthcare providers improve the accuracy and timing of disease detection and management. The company offers a portfolio of laboratory tests, primarily under its AVISE brand, that support the diagnosis, prognosis, and monitoring of complex autoimmune and rheumatic conditions by using proprietary biomarkers and innovative testing technologies. It emphasizes patient-centered care and scientific discovery, aiming to provide clarity in clinical decision-making and enable more effective treatment strategies for conditions such as lupus and rheumatoid arthritis, while contributing to improved outcomes through research-driven diagnostic innovation.Explore more
Exagen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Exagen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Exagen is spiking on competitors!
Click to see if Exagen had a recent Job posting/layoffs
Check if Exagen has recently received funding, and reach out quickly before it becomes old news!
Exagen, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Exagen recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Exagen has new funding data
Congratulate Masked Content for being promoted to Masked Content at Exagen
Product Launch: Get notified when Exagen launches new products
Recommended Actions
Find VP level buyers at Exagen
Find 3 more new buyers
Compare Similar Companies to Exagen
Compare insights from companies similar to Exagen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Exagen is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Exagen is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Exagen.
Exagen financials insights
Gather financial insights about Exagen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Series D
$5M
Debt
$25M
2014
Debt
$4M
2015
Debt
$1.8M
Debt
$3M
2016
Series E
$16.8M
Debt
$2.1M
2017
Series F
$23M
Debt
$25M
2019
Private Equity
$22.6M
Stock Offering
$58M
2025
Stock/Share Issuance
$20.2M
Exagen Tech Stack
A closer look at the technologies used by Exagen
See more technologies
Most Recent Scoops
Person-Based
Earnings, Finance, Financial Operations
Person-Based
Earnings, Financial Reporting, Finance
Event
will be presenting seven abstracts at the International Congress on Autoimmunity in Prague later this month, with additional abstract presentations expected at ACR later in the year.
Events
Earnings
reported an adjusted EBITDA loss of $9.8 million for 2025, which excludes depreciation and non-cash stock compensation expense, representing a moderate improvement over 2024.
Earnings, Finance
Pain Point
Pain Point, Medical Research
Exagen News & Media
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Exagen reports published real-world evidence showing AVISE Lupus outperformed conventional tests and identified 25% of patients otherwise missed.Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q1 2026 Earnings Call May 11, 2026 8:30 AM EDTCompany ParticipantsTina Jacobsen - Vice President of Investor RelationsJohn Aballi - CEO,...Exagen Q1 Earnings Call Highlights
Exagen (NASDAQ:XGN) reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician adoption helped offset a weather-related disruption early in the quarter. The autoimmune diagnosticsExagen Inc. Reports First Quarter 2026 Results
Delivers record total revenue and AVISE(R) CTD average selling price Delivers record total revenue and AVISE(R) CTD average selling price
Read more news
Top Healthcare Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Exagen
Sign Up For FreeTo access detailed company insights
Exagen is a United Statesbased life sciences company that develops and commercializes advanced diagnostic testing solutions focused on autoimmune diseases, helping healthcare providers improve the accuracy and timing of disease detection and management. The company offers a portfolio of laboratory tests, primarily under its AVISE brand, that suppor... Read More
